Boehringer Ingelheim India in association with Muskan Foundation inaugurates first-of-its kind facility for children with Multiple Disabilities at Bai Jerbai Wadia Hospital
by Prashant Kapadia/NHN
A unique facility focused to empower children with multiple disabilities
To educate children communicate effectively and cultivate behavioural change essential in the daily life
The objective of the facility is to enable these children live independent, self-confident and happy lives
Mumbai, October 9, 2018: Boehringer Ingelheim, one of the world’s leading pharmaceutical company, inaugurated ‘first-of-its-kind’ facility for children with multiple disability at Bai Jerbai Wadia Hospital in association with Muskan foundation. The program in Mumbai, designed with an aim to train the visually impaired children accompanied by an additional disabilities to help communicate effectively and develop modification to their behavior essential for their daily routine. The facility was inaugurated by Manuela Pastore, Global Director as a part of the social entrepreneurial initiative Making More health at Boehringer Ingelheim.
Explaining the thought process behind the association, Sharad Tyagi, Managing Director, Boehringer Ingelheim said, “Boehringer Ingelheim wishes to reinforce the importance of having a normal life for children with special needs and this initiative is a step in that direction. This is one of the many programs undertaken by us to fulfill our commitment towards the people of the country. At the facility, we hope to enable the children with multiple disabilities lead a normal life.
*In India there are 20.42 lakh disabled children who are aged between 0 and 6 years. Out of which 14.52 lakh and 5.9 lakh children live in rural and urban areas respectively. Of them, 11.04 lakh are male and 9.38 lakh are female children. Among them, 1.49 lakh children have multiple disabilities. Ms. Dipti Gandhi, Hon Director of Muskan Foundation for People with Multiple Disabilities said “Through this unique facility we have tried to touch the lives of 102 children who are visually impaired accompanied by an additional disability, out of which 10 children come from outside Mumbai to get trained at our center. At the center, we have an Individual education program, specially designed keeping in mind the needs and requirements of every child for his growth. We have planned a multi-facet program to train these children which includes a therapist, parent, and a special educator”.
“Under the umbrella of our global initiative we make positive impact happen – in a very tangible way. I am very proud together with local stakeholders we could inaugurate this facility today. It makes the further milestone in our journey in India where we are running huge health programs for tribes in Tamil Nadu & Kerala” said Manuela Pastore, Global Director -Making More health at Boehringer Ingelheim
Emphasizing on the unique initiative at the hospital, Dr. Minnie Bodhanwala, CEO of Bai Jerbai Wadia Hospital for Children said “The initiative is planned keeping in mind the entire medical and mental support system necessary for children with special needs. As we have a hospital thoughtfully designed for children, unique facility to train children with multiple disabilities was a need. We have special programs designed considering a totally new approach required for every child who enrolls”
At the Facility, the children are trained to manage their disabilities with a multi-disciplinary approach to ensure that they are able to make a lasting difference in their health and life. While the facility also focuses on educating the parents who will then receive comprehensive training for effective management of these children at home.
Currently the facility has over 100+ children with multiple disabilities like blindness, deafness, cerebral palsy etc.
Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com
Previous Article